Testing for Genetic Variants Informed the Use of Cancer Risk Assessments
Genetic testing provided important information beyond personal and family history.
Genetic testing provided important information beyond personal and family history.
Addition of surgery prior to chemotherapy does not prolong overall survival in recurrent ovarian cancer.
The first multitumor exceptional responder program in Australia is under way, adding to the growing worldwide effort to identify patient DNA changes and biomarkers of response.
In a recent paper published in the Journal of Clinical Oncology, the authors recommended using adjuvant and maintenance bevacizumab to treat a patient with stage IIIc ovarian cancer following an optimal (R0) resection.
Zejula, a poly(ADP-ribose) polymerase (PARP) inhibitor, is also approved for maintenance treatment in adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
There is interest in determining whether antiangiogenic therapies can act synergistically with checkpoint blockade in the setting of recurrent ovarian cancer.
The benefit was seen in an all-comers population, according to the presenters at ESMO Congress 2019.
Results of a prospective study comparing effectiveness of ultrasound screening and salpingo-oophorectomy in preventing ovarian cancer are presented.
Dr Marasco explains that CAR-T therapies are really “cellular therapies that work by way of gene manipulation,” and describes a method through which he hopes CAR-T can produce durable, long-term treatments for solid tumors.
Novel noncontraceptive benefit seen for all intrauterine devices.